| Trial ID: | L3770 |
| Source ID: | NCT05902468
|
| Associated Drug: |
Ursodeoxycholic Acid
|
| Title: |
Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Ursodeoxycholic acid
|
| Outcome Measures: |
Primary: Glycemic control, Fasting blood glucose, glycated hemoglobin, 12 weeks | Secondary: Lipid profile, Total cholesterol, triglycerides, HDL-cholesterol, and LDL-cholesterol, 12 weeks|Insulin resistance, Fasting insulin, HOMA-IR, 12 weeks|Oxidative stress marker, Serum malondialdehyde, 12 weeks|Inflammation marker, Interleukin-6, high mobility group box-1, 12 weeks|Serum asprosin, 12 weeks
|
| Sponsor/Collaborators: |
Sponsor: Tanta University | Collaborators: Menoufia University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2|PHASE3
|
| Enrollment: |
88
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2023-06-28
|
| Completion Date: |
2024-11-28
|
| Results First Posted: |
|
| Last Update Posted: |
2023-06-15
|
| Locations: |
Faculty of medicine, Tanta University, Tanta, El-Gharbia, 31527, Egypt|Faculty of Medicine, Menoufia University, Shibīn Al Kawm, Menoufia, 32511, Egypt
|
| URL: |
https://clinicaltrials.gov/show/NCT05902468
|
